Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

• Main Authors: Aaron T Gerds (Author), Claudia Castro (Author), Frank Snopek (Author), Megan M Flynn (Author), Alexandra G Ellis (Author), Meredith Mannin (Author), Ray Urbanski (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of thi...